Targeting the proteasome pathway

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 5, 2009, Pages 605-621

  Tsukamoto, Sachiko ^a   Yokosawa, Hideyoshi ^b,c,d  

^a CHIBA UNIVERSITY   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Cancer; Drug discovery; Proteasome; Proteasome inhibitor; Targeted therapy; Ubiquitin

Indexed keywords

BELACTOSIN A; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARBOPLATIN; CARFILZOMIB; CEP 18770; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPOXOMICIN; FELLUTAMIDE B; GEMCITABINE; GLIDOBACTIN A; IRINOTECAN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MELPHALAN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PACLITAXEL; PR 171; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SYRINGOLIN A; THALIDOMIDE; TYROPEPTIN A; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

BREAST CANCER; CLINICAL TRIAL; COLON CANCER; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PROTEIN TARGETING; REVIEW; STOMACH CANCER;

ACETYLCYSTEINE; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; BORONIC ACIDS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; LACTONES; NEOPLASMS; PEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; UBIQUITIN; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINS;

EID: 67649604329     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902866851     Document Type: Review

References (105)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479 • This paper and reference 2 are comprehensive reviews that describe the ubiquitin-proteasome pathway. (Pubitemid 28411135)
2. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2001;82:373-428 • This paper and reference 1 are comprehensive reviews that describe the ubiquitin-proteasome pathway.
3. Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 2008;9:826-838
4. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designated for controlled proteolysis. Annu Rev Biochem 1999;68:1015-1068 • A comprehensive review that describes the structure and functions of the 26S proteasome. (Pubitemid 29449214)
5. DeMartino GN, Gillette TG. Proteasomes: mechanisms for all reasons. Cell 2007;128:659-662
6. Sánchez-Serrano I. Success in translational research: lessons from the development of bortezomib. Nat Rev Drug Discov 2006;5:107-114
7. Feling RH, Buchanan GO, Mincer TJ, et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed 2003;42:355-357
8. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001;2:179-187 (Pubitemid 33675742)
9. Murata S, Sasaki K, Kishimoto T, et al. Regulation of CD8+ T cell development by thymus-specific proteasomes. Science 2007;316:1349-1353
10. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771
11. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003;8:307-315 (Pubitemid 36332222)
12. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-338
13. Vinitsky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 1992;31:9421-9428
14. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class 1 molecules. Cell 1994;78:761-771
15. Bross PF, Kane RC, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-3964
16. O-mura S, Fujimoto T, Otoguro K, et al. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot 1991;44:113-116
17. O-mura S, Matsuzaki K, Fujimoto T, et al. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot 1991;44:117-118
18. Fenteany G, Standaert RF, Reichard GA, et al. A β-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci USA 1994;91:3358-3362
19. Dick LR, Cruikshank AA, Grenier L, et al. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J Biol Chem 1996;271:7273-7276 (Pubitemid 26111059)
20. Fenteany G, Standaert RF, Lane WS, et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995;268:726-731
21. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003;115:235-245 (Pubitemid 36578922)
22. Macherla VR, Mitchell SS, Manam RR, et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005;48:3684-3687 (Pubitemid 40776841)
23. Williams PG, Buchanan GO, Feling RH, et al. New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J Org Chem 2005;70:6196-6203 (Pubitemid 41076500)
24. Reddy LR, Fournier JF, Reddy BVS, Corey EJ. An efficient, stereocontrolled synthesis of a potent omuralide-salinosporin hybrid for selective proteasome inhibition. J Am Chem Soc 2005;127:8974-8976 (Pubitemid 40897588)
25. McGlinchey RP, Nett M, Eustáquio AS, et al. Engineered biosynthesis of antiprotealide and other unnatural salinosporamide proteasome inhibitors. J Am Chem Soc 2008;130:7822-7823 (Pubitemid 351875047)
26. Eustáquio AS, Moore BS. Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome. Angew Chem Int Ed 2008;47:3936-3938
27. Stadler M, Bitzer J, Mayer-Bartschmid A, et al. Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial Streptomycete. J Nat Prod 2007;70:246-252 (Pubitemid 46447638)
28. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Cancer Cell 2006;14:451-456 •• This paper reports the crystal structure of the proteasome in a complex with bortezomib and shows the specificity and binding mode of bortezomib to the proteasome. (Pubitemid 43363478)
29. Berkers CR, Verdoes M, Lichtman E, et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005;2:357-362
30. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005;8:407-419 •• This paper describes antitumor activity of an orally active salinosporamide A, distinct from bortezomib.
31. Hanada M, Sugawara K, Kaneta K, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 1992;45:1746-1752 (Pubitemid 23015454)
32. Meng L, Mohan R, Kwok BHB, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999;96:10403-10408
33. Groll M, Schellenberg B, Bachmann AS, et al. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008;452:755-759
34. Wäspi U, Blanc D, Winkler T, et al. Syringolin, a novel peptide elicitor from Pseudomonas syringae pv. syringae that induces resistance to Pyricularia oryzae in rice. Mol Plant Microbe Interact 1998;11:727-733
35. Amrein H, Makart S, Granado J, et al. Functional analysis of genes involved in the synthesis of syringolin A by Pseudomonas syringae pv. syringae B301D-R. Mol Plant Microbe Interact 2004;17:90-97
36. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-360 •• This paper reviews antineoplastic activity of bortezomib and clinical trials with bortezomib. (Pubitemid 38579481)
37. Pajonk F, Pajonk K, McBride WH. Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000;47:1025-1032 (Pubitemid 30345603)
38. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-2380 (Pubitemid 36302084)
39. Podar K, Gouill SL, Zhang J, et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 2008;27:721-731
40. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 2007;43:1125-1133
41. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-1657
42. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917
43. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008:140:625-634 (Pubitemid 351300910)
44. Dorsey BD, Iqbal M, Chatterjee S, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008;51:1068-1072 (Pubitemid 351304717)
45. Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008;111:2765-2775
46. Groll M, Huber R, Potts BCM. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006;128:5136-5141 •• This paper reports the crystal structures of the proteasome in a complex with salinosporamides and shows their binding mode to the proteasome.
47. Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 2006;95:961-965 (Pubitemid 44606819)
48. Ruiz S, Krupnik Y, Keating M, et al. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006;5:1836-1843
49. Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110:267-277
50. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675 (Pubitemid 46224166)
51. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-3290
52. Shigemori H, Wakuri S, Yazawa K, et al. Fellutamides A and B, cytotoxic peptides from a marine fish-possessing fungus Penicillium fellutanum. Tetrahedron 1991;47:8529-8534
53. Yamaguchi K, Tsuji T, Wakuri S, et al. Stimulation of nerve growth factor synthesis and secretion by fellutamide A in vitro. Biosci Biotechnol Biochem 1993;57:195-199
54. Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol 2008;15:501-512 (Pubitemid 351658945)
55. Momose I, Sekizawa R, Hashizume H, et al. Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. I. Taxonomy, isolation, physico-chemical properties and biological activities. J Antibiot 2001;54:997-1003
56. Momose I, Sekizawa R, Hirosawa S, et al. Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. II. Structure determination and synthesis. J Antibiot 2001;54:1004-1012 (Pubitemid 34110867)
57. Momose I, Umezawa Y, Hirosawa S, et al. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg Med Chem Lett 2005;15:1867-1871
58. Asai A, Tsujita T, Sharma SV, et al. A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. Biochem Pharmacol 2004;67:227-234
59. Yoshida K, Yamaguchi K, Sone T, et al. Synthesis of 2,3- and 3,4-methanoamino acid equivalents with stereochemical diversity and their conversion into the tripeptide proteasome inhibitor belactosin A and its highly potent cis-cyclopropane stereoisomer. Org Lett 2008;10:3571-3574
60. Groll M, Larionov OV, Huber R, de Meijere A. Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. Proc Natl Acad Sci USA 2006;103:4576-4579
61. Koguchi Y, Kohno J, Nishino M, et al. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. J Antibiot 2000;53:105-109
62. Kohno J, Koguchi Y, Nishino M, et al. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei Sacc. TC 1093. J Org Chem 2000;65:990-995 (Pubitemid 30117368)
63. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001;311:543-548 (Pubitemid 32816588)
64. Groll M, Götz M, Kaiser M, et al. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem Biol 2006;13:607-614
65. Inoue M, Zhai H, Sakazaki H, et al. TMC-95A, a reversible proteasome inhibitor, induces neurite outgrowth in PC12 cells. Bioorg Med Chem Lett 2004;14:663-665
66. Sasse F, Steinmetz H, Schupp T, et al. Argyrins, immunosuppressive cyclic peptides from myxobacteria. I. Production, isolation, physico-chemical and biological properties. J Antibiot 2002;55:543-551
67. kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008;14:23-35 • This paper reports the identification of argyrin A as a proteasome inhibitor and presents evidence that argyrin A kills cancer cells via mechanisms distinct from those elicited by bortezomib.
68. Tsukamoto S, Tatsuno M, van Soest RWM, et al. New polyhydroxy sterols: proteasome inhibitors from a marine sponge Acanthodendrilla sp. J Nat Prod 2003;66:1181-1185 (Pubitemid 37204215)
69. Tsukamoto S, Koimaru K, Ohta T. Secomycalolide A: a new proteasome inhibitor isolated from a marine sponge of the genus Mycale. Mar Drugs 2005;3:29-35 (Pubitemid 41001102)
70. Tsukamoto S, Wakana T, Koimaru K, et al. 7-Hydroxy-3-(4-hydroxybenzyl) chroman and broussonin B: neurotrophic compounds, isolated from Anemarrhena asphodeloides BUNGE, function as proteasome inhibitors. Biol Pharm Bull 2005;28:1798-1800
71. Lim HS, Archer CT, Kodadek T. Identification of a peptoid inhibitor of the proteasome 19S regulatory particle. J Am Chem Soc 2007;129:7750-7751 (Pubitemid 46998162)
72. Ventii KH, Wilkinson KD. Protein partners of deubiquitinating enzymes. Biochem J 2008;414:161-175
73. Verma R, Aravind L, Oania R, et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 2002;298:611-615
74. Deveraux Q, van Nocker S, Mahaffey D, et al. Inhibition of ubiquitin-mediated proteolysis by the Arabidopsis 26S protease subunit S5a. J Biol Chem 1995;270:29660-29663 (Pubitemid 26001627)
75. Husnjak K, Elsasser S, Zhang N, et al. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 2008;453:481-488
76. Schreiner P, Chen X, Husnjak K, et al. Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction. Nature 2008;453:548-552
77. Elsasser S, Finley D. Delivery of ubiquitinated substrates to protein-unfolding machines. Nat Cell Biol 2005;7:742-749 • This paper reviews the system functioning in delivery of ubiquitinated client proteins to the proteasome. (Pubitemid 41079042)
78. Verma R, Oania R, Graumann J, Deshaies RJ. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 2004;118:99-110 • This paper reports evidence that the respective ubiquitin receptors are able to discriminate proteasome substrates. (Pubitemid 38902817)
79. Bays NW, Hampton RY. Cdc48-Ufd1-Npl4: stuck in the middle with Ub. Curr Biol 2002;12:R366-71 (Pubitemid 34514362)
80. Richly H, Rape M, Braun S, et al. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005;120:73-84
81. Lüders J, Demand J, Höhfeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J Biol Chem 2000;275:4613-4617 (Pubitemid 30108845)
82. Demand J, Alberti S, Patterson C, Höhfeld J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol 2001;11:1569-1577 (Pubitemid 32978521)
83. Glockzin S, Ogi FX, Hengstermann A, et al. Involvement of the DNA repair protein hHR23 in p53 degradation. Mol Cell Biol 2003;23:8960-8969
84. Tsukamoto S, Yamashita K, Tane K, et al. Girolline, an antitumor compound isolated from a sponge, induces G2/M cell cycle arrest and accumulation of polyubiquitinated p53. Biol Pharm Bull 2004;27:699-701
85. Saeki Y, Isono E, Oguchi T, et al. Intracellularly inducible, ubiquitin hydrolase-insensitive tandem ubiquitins inhibit the 26S proteasome activity and cell division. Genes Genet Syst 2004;79:77-86
86. Verma R, Peters NR, D'Onofrio M, et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 2004;306:117-120
87. Verma R, Chen S, Feldman R, et al. Proteasomal proteomics: identification of nucleotide-sensitive proteasome-interacting proteins by mass spectrometric analysis of affinity-purified proteasomes. Mol Biol Cell 2000;11:3425-3439
88. Guerrero C, Tagwerker C, Kaiser P, Huang L. An integrated mass spectrometry-based proteomic approach: quantitative analysis of tandem affinity-purified in vivo cross-linked protein complexes (QTAX) to decipher the 26S proteasome-interacting network. Mol Cell Proteomics 2006;5:366-378 (Pubitemid 43329314)
89. Schmidt M, Hanna J, Elsasser S, Finley D. Proteasome-associated proteins: regulation of a proteolytic machine. Biol Chem 2005;386:725-737 (Pubitemid 41448153)
90. Crosas B, Hanna J, Kirkpatrick DS, et al. Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities. Cell 2006;127:1401-1413
91. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6:9-20 • This paper and reference 92 are comprehensive reviews that focus on the structures and functions of ubiquitin ligases. (Pubitemid 40064895)
92. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008;14:10-21 • This paper and reference 91 are comprehensive reviews that focus on the structures and functions of ubiquitin ligases. (Pubitemid 351885498)
93. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13:23-31 (Pubitemid 46027725)
94. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979-987
95. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848 • This paper describes novel compounds, nutlins, antagonizing the ubiquitin ligase MDM2 for the tumor suppressor p53.
96. Duncan SJ, Grüschow S, Williams DH, et al. Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J Am Chem Soc 2001;123:554-560 (Pubitemid 32105997)
97. Tsukamoto S, Yoshida T, Hosono H, et al. Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp. Bioorg Med Chem Lett 2006;16:69-71
98. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10:1321-1328
99. Sekizawa R, Ikeno S, Nakamura H, et al. Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. J Nat Prod 2002;65:1491-1493 (Pubitemid 35239640)
100. Tsukamoto S, Hirota H, Imachi M, et al. Himeic acid A: a new ubiquitin-activating enzyme inhibitor isolated from a marine-derived fungus, Aspergillus sp. Bioorg Med Chem Lett 2005;15:191-194
101. Yang Y, Kitagaki J, Dai RM, et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007;67:9472-9481
102. Tsukamoto S, Takeuchi T, Rotinsulu H, et al. Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis. Bioorg Med Chem Lett 2008;18:6319-6320
103. Laine A, Topisirovic I, Zhai D, et al. Regulation of p53 localization and activity by Ubc13. Mol Cell Biol 2006;26:8901-8913
104. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008;111:1654-1664
105. Kuhn DJ, Hunsucker SA, Chen Q, et al. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and non-specific proteasome inhibitors. Blood 2009, published online 2 December, 2008, doi: 10.1182/blood-2008-07-171637